摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]哌啶 | 852227-97-5

中文名称
1-[3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]哌啶
中文别名
3-哌啶子基苯基硼酸,频哪醇酯
英文名称
1-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)piperidine
英文别名
1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine
1-[3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]哌啶化学式
CAS
852227-97-5
化学式
C17H26BNO2
mdl
——
分子量
287.21
InChiKey
IIUXWPXCCXVCPD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    156 °C
  • 沸点:
    419.4±28.0 °C(Predicted)
  • 密度:
    1.04±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.98
  • 重原子数:
    21
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.65
  • 拓扑面积:
    21.7
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2934999090
  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:f4b3f7b62140ff7d9187b93acf9598ed
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 3-Piperidinophenylboronic acid, pinacol ester
Synonyms: 1-[3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]piperidine

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 3-Piperidinophenylboronic acid, pinacol ester
CAS number: 852227-97-5

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C17H26BNO2
Molecular weight: 287.2

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    1-[3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]哌啶1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物potassium acetate 、 palladium diacetate 、 caesium carbonate4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下, 以 1,4-二氧六环 为溶剂, 反应 24.0h, 生成 1-(5-((5-chloro-4-(3-(piperidin-1-yl)phenyl)pyrimidin-2-yl)amino)pyridin-3-yl)pyrrolidin-2-one
    参考文献:
    名称:
    INHIBITORS AND DEGRADERS OF PIP4K PROTEIN
    摘要:
    Provided are compounds and compositions which modulate the level or activity of PIP4K2C. Also provided are methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of a PIP4K2C, comprising administering the compounds and compositions.
    公开号:
    WO2024107746A1
  • 作为产物:
    描述:
    3-(N-哌啶基)溴苯联硼酸频那醇酯(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 作用下, 以 1,4-二氧六环二氯甲烷 为溶剂, 反应 12.0h, 以61.3%的产率得到1-[3-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯基]哌啶
    参考文献:
    名称:
    Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis
    摘要:
    Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns by using chemical scaffolds from drugs approved for other indications can speed up drug discovery for neglected diseases. We demonstrated recently that the 4-anilinoquinazolines lapatinib (GW572016, 1) and canertinib (CI-1033) kill T. brucei with low micromolar EC50 values. We now report promising activity of analogues of 1, which provided an excellent starting point for optimization of the chemotype. Our compound optimization that has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly potent, orally bioavailable inhibitor of trypanosome replication. At the cellular level, 23a blocks duplication of the kinetoplast and arrests cytokinesis, making it a new chemical tool for studying regulation of the trypanosome cell cycle.
    DOI:
    10.1021/jm400349k
点击查看最新优质反应信息

文献信息

  • [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT D'UNE MALADIE
    申请人:BIOMARIN PHARM INC
    公开号:WO2020257487A1
    公开(公告)日:2020-12-24
    Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.
    本文描述了化合物、制备这种化合物的方法、含有这种化合物的药物组合物和药物,以及使用这种化合物治疗或预防与甘氧酸代谢缺陷相关的疾病或紊乱的方法,例如与甘氧酸氧化酶(GO)或草酸代谢变化相关的疾病或紊乱。这些疾病或紊乱包括与产生过多草酸相关的甘氧酸代谢紊乱,例如原发性高草酸尿症。
  • [EN] GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE<br/>[FR] INHIBITEURS DE GLYCOLATE OXYDASE POUR LE TRAITEMENT DE MALADIES
    申请人:BIOMARIN PHARM INC
    公开号:WO2019133770A3
    公开(公告)日:2019-08-15
  • Kinase Scaffold Repurposing for Neglected Disease Drug Discovery: Discovery of an Efficacious, Lapatanib-Derived Lead Compound for Trypanosomiasis
    作者:Gautam Patel、Caitlin E. Karver、Ranjan Behera、Paul J. Guyett、Catherine Sullenberger、Peter Edwards、Norma E. Roncal、Kojo Mensa-Wilmot、Michael P. Pollastri
    DOI:10.1021/jm400349k
    日期:2013.5.23
    Human African trypanosomiasis (HAT) is a neglected tropical disease caused by the protozoan parasite Trypanosoma brucei. Because drugs in use against HAT are toxic and require intravenous dosing, new drugs are needed. Initiating lead discovery campaigns by using chemical scaffolds from drugs approved for other indications can speed up drug discovery for neglected diseases. We demonstrated recently that the 4-anilinoquinazolines lapatinib (GW572016, 1) and canertinib (CI-1033) kill T. brucei with low micromolar EC50 values. We now report promising activity of analogues of 1, which provided an excellent starting point for optimization of the chemotype. Our compound optimization that has led to synthesis of several potent 4-anilinoquinazolines, including NEU617, 23a, a highly potent, orally bioavailable inhibitor of trypanosome replication. At the cellular level, 23a blocks duplication of the kinetoplast and arrests cytokinesis, making it a new chemical tool for studying regulation of the trypanosome cell cycle.
  • INHIBITORS AND DEGRADERS OF PIP4K PROTEIN
    申请人:[en]LARKSPUR BIOSCIENCES
    公开号:WO2024107746A1
    公开(公告)日:2024-05-23
    Provided are compounds and compositions which modulate the level or activity of PIP4K2C. Also provided are methods for treating diseases or conditions by modulating (e.g., reducing) the level or activity of a PIP4K2C, comprising administering the compounds and compositions.
查看更多